EMPAGLIFLOZIN AND CANAGLIFLOZIN ATTENUATE INFLAMMATORY CYTOKINES INTERFERON-λ, TUMOR NECROSIS FACTOR-α, INTERLEUKIN-6: POSSIBLE MECHANISM OF DECREASING CARDIOVASCULAR RISK IN DIABETES MELLITUS
| Autor: | Linda Tan, Stanley A. Tan |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Canagliflozin
biology business.industry 030209 endocrinology & metabolism 030204 cardiovascular system & hematology Pharmacology medicine.disease Proinflammatory cytokine 03 medical and health sciences 0302 clinical medicine Interferon Diabetes mellitus medicine Empagliflozin biology.protein Tumor necrosis factor alpha SGLT2 Inhibitor Cardiology and Cardiovascular Medicine Interleukin 6 business medicine.drug |
| Zdroj: | Journal of the American College of Cardiology. 71:A1830 |
| ISSN: | 0735-1097 |
| DOI: | 10.1016/s0735-1097(18)32371-4 |
| Popis: | SGLT2 inhibitor canagliflozin decreases Hgb A1c better than empagliflozin; but empagliflozin decreases the cardiovascular risk in diabetics more than canagliflozin. Inflammatory cytokines Interferon-λ (IFN-λ), Tumor Necrosis Factor-α (TNF-α), & Interleukin-6 (IL-6) are implicated as |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|